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Acute intermittent porphyria (AIP) is a genetic disorder
of the synthesis of heme caused by a deficiency in
hydroxymethylbilane synthase (HMBS), leading to the
overproduction of the porphyrin precursors δ-aminolevulinic
acid and porphobilinogen. The aim of this study is to describe
the clinical and biological characteristics, the renal pathology,
and the cellular mechanisms of chronic kidney disease
associated with AIP. A total of 415 patients with HMBS
deficiency followed up in the French Porphyria Center were
enrolled in 2003 in a population-based study. A follow-up
study was conducted in 2013, assessing patients for clinical,
biological, and histological parameters. In vitro models were
used to determine whether porphyrin precursors promote
tubular and endothelial cytotoxicity. Chronic kidney disease
occurred in up to 59% of the symptomatic AIP patients, with
a decline in the glomerular filtration rate of ~ 1ml/min per
1.73m2 annually. Proteinuria was absent in the vast
majority of the cases. The renal pathology was a chronic
tubulointerstitial nephropathy, associated with a fibrous
intimal hyperplasia and focal cortical atrophy. Our
experimental data provide evidence that porphyrin
precursors promote endoplasmic reticulum stress, apoptosis,
and epithelial phenotypic changes in proximal tubular cells.
In conclusion, the diagnosis of chronic kidney disease
associated with AIP should be considered in cases of chronic
tubulointerstitial nephropathy and/or focal cortical atrophy
with severe proliferative arteriosclerosis.
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Acute intermittent porphyria (AIP) is an inherited autosomal
dominant disorder of the synthesis of heme owing to a defect
in hydroxymethylbilane synthase (HMBS).1,2 The prevalence
of symptomatic disease in Europe is 1/180,000,3 but the
prevalence of HMBS mutations in the general population is
1/1675,4 suggesting that the prevalence of the disease, based
on acute AIP symptoms, is underestimated, in part because
the clinical manifestations are nonspecific and clinicians are
often unaware of the underlying diagnosis. HMBS deficiency
fosters the accumulation of the porphyrin precursors
δ-aminolevulinic acid (ALA) and porphobilinogen (PBG;
Supplementary Figure S1 online). In situations in which heme
synthesis is stimulated in the liver, such as during the
menstrual cycle, caloric restriction, infection, or the use of
medications that induces P450 cytochromes synthesis, the
serum concentrations of ALA and PBG greatly increase. This
increase may prompt acute symptoms of the disease to occur.
The acute clinical expression of AIP is the neurovisceral
attack. An AIP acute attack is mainly characterized by severe
abdominal pain, often accompanied by nausea, vomiting,
tachycardia, and hypertension. The acute attacks may be
complicated by neurologic findings: agitation, confusion,
peripheral neuropathy, and coma.
During AIP attacks, ALA and PBG are massively excreted
in urine, where their presence confirms the diagnosis.5 The
treatment of AIP relies on the correction/avoidance of
precipitating factors, hydration, nutritional support, pain
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relief, and, in severe cases, administration of heme arginate,
which inhibits ALA synthase and reduces ALA and PBG
synthesis.6 Neurovisceral attacks usually resolve within 4 days.
The long-term complications of AIP include hepatic
carcinoma (HCC) without cirrhosis,7–9 and chronic kidney
disease (CKD). The association of CKD with AIP has been
described, and few reports have documented a chronic
tubulointerstitial nephropathy with mild hypertension.10–13
No large-scale follow-up study of CKD associated with AIP
has been conducted to date, and the biological mechanisms
that promote kidney injury are not known. We conducted
this population-based, observational study to provide a
comprehensive survey of the clinical, biological, and
pathological characteristics of CKD associated with AIP
(hereafter referred to as PAKD, for porphyria associated
kidney disease), and we used in vitro models to provide
mechanistic insights into how porphyrin precursors might
promote kidney injury.
RESULTS
CKD is highly prevalent among AIP patients
In 2003, the French Porphyria Center performed an
observational study of a population of 415 patients (184
AIP patients and 231 asymptomatic carriers) who provided a
serum creatinine measurement. The demographic character-
istics of this population are shown in Supplementary Table S1
online. As expected, most of the patients were lean women,
with a median age of 50 years, with a prevalence of liver
cancer significantly higher (3%) compared with the asympto-
matic carriers (0.4%). Ten years later, in 2013, these 415
patients were contacted by mail to provide responses to a
detailed questionnaire and to undergo some specific biologi-
cal measurements at the steady state of the disease (see
Supplementary Materials and Methods online). The response
rate to this survey was 33% (136/415), with 74 AIP patients
and 62 asymptomatic carriers (the ‘2013 cohort’). The
demographic and medical characteristics of this cohort are
listed in Table 1; except for estimated glomerular filtration
rate (eGFR) and age, there was no difference between the
2003 and 2013 cohorts at these two time points. The majority
of the AIP patients were female, with no significant difference
in age compared with the asymptomatic carriers. As expected,
the ALA and PBG urinary concentrations at the steady state
were significantly lower in asymptomatic carriers compared
with the AIP patients.
CKD, defined as eGFRo60 ml/min per 1.73 m2, was
diagnosed in 59% of the AIP patients, compared with 11%
in the asymptomatic carriers (Table 1 and Figure 1a). The
renal function observed in asymptomatic carriers was similar
to the general population.14,15 Proteinuria/creatininuria ratio
was negligible. Hypertension was frequent in this population,
as 62% of the AIP patients were hypertensive, compared with
42% of the asymptomatic carriers (P= 0.006). Among the 184
AIP patients in the 2003 cohort, 5 (2.7%) have been identified
as having reached end-stage renal disease between 2003 and
2013, and 2 of them received a kidney transplant.
AIP contributes to CKD
Hypertension and ‘AIP patients’ status occurred more
frequently in individuals with CKD (Table 2), and the
unadjusted odds ratio for hypertension was 3.8 (95%
confidence interval (CI) 1.8–8.1, P= 0.0004) and for AIP
patients the odds ratio was 11.9 (95% CI 4.6–26, Po0.0001).
As AIP patients are frequently hypertensive,10 and hyperten-
sion contributes to CKD, we determined whether AIP was
independently associated with CKD (defined by an eGFRo60
Table 1 |Clinical and laboratory characteristics of the ‘2013 cohort’ (n=136)
AIP patients (n=74) Asymptomatic carriers (n=62) P-value
Age (years) 65 (56–72) 59 (51–76) 0.3
Time since AIP diagnosis (years) 28 (22–32) — —
Chronic AIP (44 crisis/year)—n (%) 4 (5.5) — —
Female sex—n (%) 62 (87) 41 (68) 0.002
Hypertension—n (%) 46 (62) 25 (42) 0.006
Diabetes—n (%) 2 (3) 3 (5) 0.6
2003 eGFR (ml/min per 1.73m2) 60 (48–74) 78 (70–88) o0.0001
2013 eGFR (ml/min per 1.73m2) 51 (41–67) 84 (70–93) o0.0001
2003 CKD—n (%)a 36 (48) 5 (8) o0.0001
2013 CKD—n (%)a 44 (59) 7 (11) o0.0001
ESRD—n (%)b 5 (6.7) 0 o0.0001
Kidney transplantation 2 (2.7) 0 —
Urine protein/creatinine ratio (g/mmol creatinine) 0.04 (0–0.1) 0 (0–0.07) 0.3
Serum uric acid (μmol/l) 372 (316–452) 227 (327–625) o0.0001
Urine ALA/creatinine (μmol/mmol creatinine)c 4 (2.7) 2.6 (1.4–2.6) o0.0001
Urine PBG/creatinine (μmol/mmol creatinine)d 2.1 (4.9–10) 0.4 (0.8–3) 0.007
Abbreviations: AIP, acute intermittent porphyria; ALA, δ-aminolevulinic acid; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal
disease; PBG, porphobilinogen.
Continuous variables are expressed as median and interquartile ranges, and nominal variables as number and proportion. The values are those obtained in 2013, except for
those specified as obtained in 2003.
aCKD is defined as eGFRo60ml/min per 1.73m2.
bESRD was defined as the need for chronic dialysis therapy or kidney transplantation.
cNormal valueo3 μmol/mmol creatinine.
dNormal valueo1 μmol/mmol creatinine.
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ml/min per 1.732). The Cochran–Mantel–Haenszel odds ratio
adjusted for hypertension was 10.4 (95% CI 3.7–30), with a
χ2 value of 28.2, Po0.0001, indicating that ‘AIP patients’ is an
explanatory variable for CKD, independently of hypertension.
The fact that urinary concentrations of PBG were higher
in individuals with CKD (Table 2) suggests that urinary
porphyrin precursors could be involved in the pathogenesis
PAKD. In line with these findings, the urinary concentrations
of neutrophil gelatinase-associated lipocalin, a marker of
tubular damage, measured in AIP patients during crisis
were higher compared with those in asymptomatic carriers,
indicating that acute production of ALA and PBG may
promote tubular injury (Supplementary Figure S2 online).
Renal function declines slowly during PAKD
The mean difference of the eGFR between 2013 and 2003 was
− 8.4± 1.9 ml/min per 1.73 m2 in the AIP patients, compared
with +1.7± 1.7 ml/min per 1.73 m2 in the asymptomatic
carriers (Po0.0001; Figure 1b). We performed a multiple
regression analysis to test whether AIP status was indepen-
dently associated with the decline of renal function between
2003 and 2013 (Delta eGFR). In a model that included
potential confounders including age, eGFR at baseline (2003
cohort), and hypertension status, only AIP status and eGFR in
2003 remained significantly correlated with eGFR decline rate
(AIP status: estimate − 7.5, 95% CI (−10.6 to − 4.3);
Po0.0001; eGFR in 2003: estimate − 0.31, 95% CI (−0.47
to − 0.16), Po0.0001), indicating that AIP is an independent
risk factor for eGFR degradation over time. Whereas the type
of mutation (null allele and missense) was not associated in
general with eGFR levels (Table 2) and eGFR decrease
between 2003 and 2013 (not shown), we observed that,
among AIP patients, the type of mutation could affect eGFR
decline rates. For example, AIP patients carrying the
c.291delG mutation (n= 6; Supplementary Table S2 online)
had a eGFR decline of − 17.1± 3 ml/min per 1.73 m2, whereas
AIP patients with the c.517C4T missense mutation (n= 5)
had a eGFR decline of − 5± 4 ml/min per 1.73 m2. There was
no difference in terms of urinary ALA or urinary PBG
between the two groups of patients. Five out of six (83%) of
291delG-positive patients were hypertensive, compared with
two out of five (40%) of 517C4T patients, but this difference
did not reach statistical significance (P= 0.2, Fisher’s exact
test). These results indicate that some specific mutations may
be associated with a worse renal prognosis.
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Figure 1 |Characteristics of renal function in acute intermittent
porphyria (AIP) patients and asymptomatic carriers. (a) Histogram
showing the distribution of the patients according to the 2013
estimated glomerular filtration rate (eGFR) levels in the 2013 cohort.
(b) Histogram showing the values of the eGFR variations between
2003 and 2013, according to AIP status (AIP patients or asymptomatic
carriers). eGFR is expressed as the mean± s.e.m. ***Po0.001
compared with asymptomatic carriers using Student’s t-test.
Table 2 |Clinical and laboratory characteristics of the ‘2013 cohort’ according the eGFR class
eGFR o60ml/min per 1.73m2 (n=54) eGFR 460ml/min per 1.73m2 (n=82) P-value
Age (years) 70 (59–77) 66 (57–74) 0.3
Female sex—n (%) 45 (83) 60 (73) 0.2
Hypertension—n (%) 39 (72) 33 (40) 0.0004
Diabetes—n (%) 2 (3) 3 (3) 1
Body mass index (kg) 23 (21–26) 23 (20–27) 0.79
AIP patients—n (%) 46 (85) 28 (34) o0.0001
HMBS nonsense mutation—n (%) 31 (57) 44 (53) 0.7
HMBS missense mutation—n (%) 14 (25) 18 (21) 0.4
Urine ALA/creatinine (μmol/mmol)a 2 (3.2–6.7) 2.8 (1.7–6.3) 0.23
Urine PBG/creatinine (μmol/mmol)b 4.4 (1.6–9.7) 1.9 (0.5–6.2) 0.01
Abbreviations: AIP, acute intermittent porphyria; ALA, δ-aminolevulinic acid; eGFR, estimated glomerular filtration rate; PBG, porphobilinogen.
Continuous variables are expressed as median and interquartile ranges and nominal variables as number and proportion.
aNormal valueo3 μmol/mmol creatinine.
bNormal valueo1 μmol/mmol creatinine.
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The tubular epithelium is injured during PAKD
We next reviewed all the available renal biopsies taken from
AIP patients included in the 2013 cohort. The histological
findings of PAKD in 14 biopsies are summarized in the
Supplementary Table S3 online. Except for sclerotic glomer-
uli, which often represented 450% of the glomeruli in the
samples analyzed, and some ischemic glomeruli, no specific
glomerular lesions were observed, and no immune deposits
were observed when an immunofluorescence analysis was
performed (not shown).
Almost all specimens displayed tubular atrophy, basal
membrane thickening, and interstitial fibrosis, which were
often associated with classical arteriosclerotic lesions of
various degrees of severity (Figures 2a and b). Moreover,
tubular sections of PAKD biopsies displayed cytoplasmic
accumulation of β-catenin and expressed vimentin (Figures
2c and d), indicative of an ongoing fibrogenic process.16,17
Yellow-brown granular aggregates were present both
within the proximal tubular cells and in the lumen
(Figure 3a), and they were negative for Perl’s coloration.
The proximal tubules accumulated numerous regular gran-
ular osmiophilic inclusions in their cytoplasm (Figures 3b
and c). The size of these particles was 100–500 nm. The
other parts of the tubule (distal and collecting tubule)
were not affected (Supplementary Figure S3A and B online),
and these aggregates were not observed within arterioles
(Supplementary Figure S3C online). In addition, ultrastruc-
ture analysis of primary cultured human renal epithelial cells
(HRECs) incubated 72 h with PBG showed accumulation of
electron-dense cytosolic granular material (Figure 3d) similar
to that observed in renal biopsies.
These data indicate that during AIP proximal tubular cells
may accumulate granular components, the composition of
which remains undetermined. One possibility is that the polar
compound PBG (consisting of one pyrrole ring, Supplementary
Figure S1 online) is incorporated within the cells where it is
transformed into less soluble uroporphyrinogen I or III (a
tetrapyrrole structure), which produces intracellular aggregates.
Supporting this, when incubated with proximal tubular cells
in culture for 24 h, PBG is totally metabolized into uro-
porphyrinogen I and III, and cannot be detected in the culture
medium (Supplementary Figure S4 online).
Figure 2 |Renal pathology of porphyria associated kidney disease (PAKD). (a) Percutaneous renal biopsy showing focal cortical atrophy
under the renal capsule and numerous sclerotic glomeruli, only one normal glomerulus, arteriosclerosis, and interstitial fibrosis. Masson’s
trichrome. Bar = 50 μM. (b) Renal biopsy showing vaso-occlusive modifications: interstitial fibrosis with numerous sclerotic glomeruli and
numerous ischemic glomeruli with severely retracted tufts. Masson’s trichrome. Bar = 50 μM. (c,d) Serial cortical section of a kidney biopsy
sample with immunostaining for β-catenin and vimentin. Normal glomeruli are naturally stained by vimentin antibodies, which serve as positive
control. Bar = 20 μM. (e) In the superficial cortex under the renal capsule, there was dense interstitial fibrosis with sclerotic glomeruli and
vascular lesions of interlobular arteries. Interlobular arteries show cellular and fibrous proliferative intimal thickening with luminal reduction.
Masson’s trichrome stain. Bar = 50 μM. (f) Intracortical arteriolopathy showing proliferation and swelling of the myocytes of the vascular media
(so-called ballooning). Marinozzi staining (silver staining). Bar = 50 μM.
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Porphyrin precursors promote epithelial injury in vitro
We next tested whether ALA and PBG could promote tubular
injury by incubating HRECs with 1 mM ALA+PBG, a
concentration that can be reached in AIP patient urine
samples upon crisis.18 When stained with the vital dyes
Hoechst 33342 and propidium iodine, HRECs appeared more
frequently apoptotic compared with the vehicle-treated cells
(Figure 4a). In addition, ALA+PBG induced PARP (polyADP
ribose polymerase) cleavage19 (Figure 4b), and HRECs were
more frequently positive for TUNEL (terminal deoxynucleo-
tidyl transferase dUTP nick end labeling) staining (Figure 4c),
which confirms that apoptosis is activated in human epithelial
cells in culture by ALA+PBG. Mechanistically, ALA and PBG
promote eiF2α phosphorylation and induce the expression of
the chaperons BiP/GRP78, PDI, and the apoptosis inducer
CHOP (Figures 4d and e), indicating that endoplasmic
reticulum stress is activated in HRECs incubated with
porphyrin precursors. In addition, HRECs exposed to ALA
and PBG accumulated the lipidated form of LC3 (LC3II),
indicating that autophagosomes accumulate in these cells, a
potential consequence of the activation of the autophagic flux
(Figure 4d).
We next tested whether ALA+PBG could induce epithelial
phenotypic changes, a process reminiscent of epithelial-to-
mesenchymal transition, which is implicated in kidney
fibrosis17,20 and which is associated with endoplasmic reti-
culum stress.20 ALA+PBG repressed E-cadherin expression
(Figure 4f), and the loss of this epithelial marker was
accompanied by a loss of the cuboid morphology of tubular
cells, and cell-to-cell contact (Figure 4g). The expression of
Slug, a transcription factor that represses E-cadherin expres-
sion,21 was increased with a nuclear localization (Figure 4g),
and β-catenin, which is anchored to E-cadherin in the plasma
membrane in resting cells, was translocated in the cytoplasm
and the nucleus, where it may regulate mesenchymal
programs such as Slug21 (Figure 4g). ALA+PBG increased
the expression of the profibrotic cytokines epidermal growth
factor and transforming growth factor-β, as well as the
expression and secretion of the proinflammatory chemokines
and cytokines interleukin (IL)-6, monocyte chemotactic
protein-1, and IL-8 (Figure 4h and Supplementary Figure
S5 online), which indicates that porphyrin precursors may
produce a proinflammatory and fibrogenic secretome.
The effects of porphyrin precursors on HREC viability and
phenotypic changes appeared to be related to a synergic effect
a
b
c
d
0.5 μm
Figure 3 | Tubular accumulation of pigmented granules. (a)
Proximal tubule sections with brown aggregates within the cytoplasm
and tubule lumen (white arrows). Black arrows denote condensed
nuclei, a feature that is suggestive of apoptosis. Bar = 10 μM. (b)
Proximal tubule section with basal membrane thickening. Dense
osmophilic aggregates are found within the cytoplasm (arrows).
Uranyl acetate-lead citrate. Bar = 5 μm. (c) Osmiophilic aggregated
granules in the cytoplasm, either embedded in a vesicle or free.
Uranyl acetate-lead citrate. Bar = 800 nm. (d) Ultrastructure analysis
by electron microscopy of human renal epithelial cell in culture
incubated for 72 h with porphobilinogen (PBG), showing
accumulation of electron-dense cytosolic granular material (white
arrows).
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between ALA and PBG because ALA and PBG induced a weak
cellular effect on cell death and epithelial phenotypic changes
when incubated alone (Supplementary Figure S5 online). In
addition, lower concentrations of ALA+PBG (100 μM) did
also promote cell death and phenotypic changes, indicating
that porphyrin precursors induce epithelial cell damage even
at low concentrations (Supplementary Figures S5A and S6
online). Taken together, these findings indicate that
porphyrin precursors directly promote epithelial cell death
and phenotypic changes that may contribute to the
pathogenesis of the tubulointerstitial lesions observed
during PAKD.
24 hours
Control
ALA+PBG
48 hours 72 hours
Co
ntr
ol
AL
A+
PB
G
Cleaved PARP
Actin
Cleaved PARP
Actin
Cleaved PARP
Actin
24 h
48 h
72h
Control ALA+PBG Control
0
1
2
3
4
ALA+PBG
Ctr
l
CHOP PDI
1
0.5
E-
ca
dh
er
in
 m
RN
A
0
0 24 48
Time (hours)
Phase contrast
Control
ALA + PBG
* *600
500
400
300
200
100
Control Control
IL
-6
co
n
ce
n
tra
tio
n
(pg
/m
l)
M
CP
-1
co
n
ce
n
tra
tio
n
(pg
/m
l)
ALA+PBG ALA+PBG
0
400
300
200
100
0
SLUG Merge MergeBeta catenin
72
*
6
4
2
Tr
an
sc
rip
ts
re
la
tiv
e
e
xp
re
ss
io
n
0
AL
A
PB
G
AL
A+
PB
G Ctr
l
AL
A
PB
G
AL
A+
PB
G
150
N
um
be
r o
f
dy
in
g 
ce
lls
 p
er
po
we
r f
ie
ld
Pe
rc
en
ta
ge
 o
f
TU
NE
L 
po
sit
ive
ce
lls
100
24 hours
48 hours
72 hours
50
0
Con
trol
ALA
+PB
G
Phospo-eiF2α
GRP78 (BiP)
LC3I
LC3II
Actin
ALA
+PB
GCtr
l
ALAPB
G
Co
ntr
ol
AL
A+
PB
G
Co
ntr
ol
AL
A+
PB
G
Co
ntr
ol
AL
A+
PB
G
E-cadherin
Actin
24 h 48 h 72 h
Figure 4 |Porphyrin precursors promote epithelial injury. (a) Human renal epithelial cells (HRECs) were incubated for various periods of time
with 1 mM δ-aminolevulinic acid (ALA)+1mM porphobilinogen (PBG), and then stained with 1 μg/ml Hoechst 33342 and 5 μg/ml propidium
iodine. The cells were analyzed by fluorescence microscopy. Bar = 50 μM. An investigator blinded to the experimental conditions estimated the
percentages of HO-PI-positive cells adhering to the dishes in three random fields per condition. (b) Immunoblotting for PARP was performed on
whole-cell lysates of HRECs that were incubated with 1 mM ALA+1mM PBG, or maintained in normal medium. Actin is shown as the loading
control. Blots are the results of three independent experiments. (c) HRECs were incubated for various periods of time with 1mM ALA+1mM PBG,
and then stained with TUNEL. Bar = 50 μM. An investigator blinded to the experimental conditions estimated the percentages of TUNEL-positive
cells adhering to the dishes in three random fields per condition. (d) Immunoblotting for phosphor-eIF2α, BiP, and actin was performed on
whole-cell lysates of HRECs that were incubated with 1 mM ALA, 1 mM PBG, 1 mM ALA+1mM PBG, or maintained in normal medium for 24 h.
Actin is shown as the loading control. Blots are the results of three independent experiments. (e) Real-time PCR analysis of CHOP and PDI
messenger-RNA (mRNA) expression in HRECs after various exposure times to 1mM ALA, 1 mM PBG, 1 mM ALA+1mM PBG, or vehicle for 24 h.
*Po0.05. (f) Left: real-time PCR analysis of E-cadherin mRNA expression in HRECs after various exposure times to 1 mM ALA+1mM PBG. Right:
representative western blot of E-cadherin expression after various incubation times of 1 mM ALA+1mM PBG. (g) Left: cellular morphology after
24-h treatment of confluent cells with 1 mM ALA+1mM PBG or vehicle determined with phase contrast microscopy. Bar = 50μm. Middle:
immunofluorescence microscopy after slug staining. Bar = 50 μm. Right: β-catenin nucleocytoplasmic redistribution after 24 h of exposure to
vehicle or 1 mM ALA+1mM. Cells were counterstained with DAPI to demonstrate the nuclei. Bar = 50 μm. (h) Graph representing the IL-6 and
monocyte chemotactic protein-1 (MCP-1) concentrations (means ± s.e.m.), measured using enzyme-linked immunosorbent assay (ELISA) using
the extracellular medium obtained from a time-course experiment on HRECs incubated with 1 mM ALA and PBG, or vehicle. The data are
representative of four independent experiments. TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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PAKD is associated with severe arteriolar lesions
Severe vascular lesions were observed in 6 out of 14 patients
in the absence of antiphospholipid syndrome (Supplementary
Table S3 online). The superficial cortex of these kidneys,
particularly in the atrophic regions and fibrous areas in
which almost all glomeruli were sclerotic (Figure 2a),
contained arterial fibrous intimal hyperplasia, characterized
by the accumulation of myofibroblasts in the intima and the
accumulation of fibrosclerotic tissue, which narrowed the
lumen (Figures 2e and f). Given that arterioles are involved in
the pathogenesis of PAKD, we tested whether porphyrin
precursors could promote endothelial injury: we incubated
human endothelial cells (HUVECs) with ALA and PBG and
monitored cellular phenotype and viability, and our results
indicated that the endothelial cells may not be a direct target
for porphyrin precursors (Supplementary Figure S7 online).
Therefore, the cellular toxic effects of ALA+PBG appear to be
specific for the epithelium.
DISCUSSION
In this study, we have demonstrated that 450% of AIP
patients have CKD, and that AIP is an independent risk factor
for CKD, even if it is usually associated with hypertension.
PAKD progresses slowly and has a mean eGFR decline of
~ 1 ml/min per 1.73 m2 annually. Histopathologically, two
types of lesions characterize PAKD: a chronic tubulointer-
stitial nephropathy, which is often associated with mild and
nonspecific arteriosclerosis, and a chronic fibrous intimal
hyperplasia associated with focal cortical atrophy. Our results
point out a direct role of porphyrin precursors in proximal
tubular cell injury, with ALA and PBG promoting epithelial
cell death and phenotypic changes that are reminiscent of
epithelial-to-mesenchymal transition, with a proinflamma-
tory and a fibrogenic profile.
Inherent to its design, response bias cannot be excluded
and may alter the real value of the prevalence of CKD
estimated by this study, as the patients who responded could
have been more seriously affected by AIP or could have
complied better with treatment. However, we report the
largest experience of CKD associated with AIP to date,
together with the longest follow-up. In 2000, a Swedish
population-based study demonstrated for the first time that
CKD could be solely owing to AIP.10 In this cohort, 34 out of
268 AIP patients and asymptomatic carriers had an eGFRo65
ml/min, which is similar to the general population.
The histopathological analyses of kidney biopsies under-
cover the previously unappreciated importance of the
arteriolopathy associated with AIP, with severe vascular
lesions of fibrous intimal hyperplasia associated with focal
cortical atrophy are reminiscent of the primary antiphos-
pholipid syndrome-associated renal vasculopathy.22 This
finding raises the question of the potential vascular toxicity
of porphyrin precursors, which is highly probable given that
ALA promotes vasoconstriction experimentally,23,24 that
abdominal symptoms are thought to be related, at least in
part, to gut ischemia,25 that brain autopsies of AIP patients
who died during crisis indicate the existence of multiple small
infarcts,26,27 and that AIP attacks may cause posterior
reversible encephalopathy.28,29
Our data strongly support a model wherein renal arterioles
and tubules are separate targets of porphyrin precursors and
that ALA and PBG promote cell epithelial phenotypic changes
and apoptosis, leading to a primitive tubulointerstitial
nephropathy. It does not exclude the fact that these injuries
could be interrelated and that tissue ischemia generated by
arterial lumen narrowing could independently fuel tubular
atrophy and interstitial fibrosis. An important issue that
remains to be resolved is the timing with which renal injuries
occur during AIP. We hypothesize that tissue injuries can
occur during crisis, when the concentrations of porphyrin
precursors peak, and can lead to a cytotoxic effect, followed
by injury resolution and subsequent reparation. In this model,
the succession of crisis and injury/reparation cycles could
progressively generate chronic lesions such as tubular
atrophy, interstitial fibrosis, and arteriosclerosis. Arguments
supporting this model come from the observation that acute
reversible renal failure frequently occurs during AIP crises.
The other, but not exclusive, model would favor the chronic
toxic effect of slightly elevated concentrations of ALA and
PBG, which would lead to slowly evolving lesions. This
hypothesis is supported by the fact that the urinary
concentration of porphyrin precursors is basally higher for
patients, with a lower eGFR compared with patients without
kidney dysfunction, in samples taken outside AIP attacks.
Animal models of AIP exist,30 but they do not displays
obvious renal lesions. In a recent study, Unzu et al.31
produced acute AIP attacks in HMBS-deficient mice by
periodically inducing phenobarbital challenge, which caused
intermittent accumulation of porphyrin precursors over a
period of 3 months. They failed to show any significant
impact on renal function and histology, except for small
inflammatory infiltrates. It was suggested that the toxic effects
of porphyrin precursors on the kidney need extended periods
of time to significantly alter renal physiology, as it occurs in
the patients who develop PAKD and who are characterized by
a relatively constant high excretion of porphyrin precursors
throughout years. In line with these results, we did not find
significant renal changes, except a slight expansion of the
extracellular matrix, even if AIP crisis are triggered with
phenobarbital injections for months, or when ALA injections
are performed which does not reproduce the pattern of
histological lesions encountered in AIP patients (data not
shown). It is possible that HBMS-deficient mice integrate
more complex pathophysiological traits, and may only partly
mimic increased urinary concentrations of ALA and PBG.
Many factors might explain the fact that HMBS-deficient mice
do not develop histological lesions similar to those observed
in human AIP. The mouse model must retain 30% of HMBS
activity to be viable. As a consequence, the severity of the
renal phenotype is likely reduced. In addition, PAKD progress
slowly, and histological lesions take years to become apparent
(like lithium nephropathy, for which no animal model exists).
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Therefore, the duration of the experiments in HMBS-
deficient mice (phenobarbital injections to promote crisis,
or ALA injections, during three months) is probably too short
to induce significant histological or functional changes that
would mimic human PAKD. Finally, the genetic background
of HMBS-deficient mice (C57/Bl6) renders them more
resistant to kidney injuries compared with other strains, such
as FVB/N.32 This may explain, at least in part, the weak renal
phenotype observed.
The exact mechanisms by which porphyrin precursors
promote cell death remain unclear. DNA damage has been
proposed as a trigger for apoptotic cell death.33 Our findings
indicate that ALA and PBG promote endoplasmic reticulum
stress and apoptosis. It is tempting to speculate that proximal
tubular cells accumulate these compounds after endocytosis,
which can spontaneously oligomerize into less soluble
uroporhyrinogen, which cannot be degraded, thereby pro-
moting cell stress. Indeed, we have provided in our study
ultrastructural and biochemical arguments for an intracellular
accumulation of uroporphyrinogen. However, the intracel-
lular disturbances leading to endoplasmic reticulum stress
remain to be deciphered. The signaling pathways implicated
in chronic tissue injuries during AIP are not known at the
molecular level, and whether the long-term kidney disease of
AIP shares common pathophysiological mechanisms with
extrarenal complications remains to be established. It is
noteworthy that in our cohort all patients who suffered from
HCC had CKD, suggesting a link between the processes.
Epithelial cells incubated with ALA+PBG secrete IL-6. IL-6 is
known to foster CKD,34–36 and IL-6 has a major role in the
development of HCC, as hepatocarcinoma progenitor cells
acquire autocrine IL-6 signaling, which stimulates their in vivo
growth and malignant progression.37 Importantly, this
recently described process occurs without preexisting cirrho-
sis, such as HCC associated with AIP. This may be a general
mechanism that drives the chronic complications of AIP and
constitutes a potential therapeutic target.
In conclusion, AIP should be considered as one of the
possible causes of chronic tubulointerstitial nephritis, or in
cases of severe arteriolopathy of unknown origin. Physicians
should be aware of this association, as HMBS deficiency is
frequent, and AIP is probably underdiagnosed, in part
because the clinical manifestations are nonspecific and
clinicians are often unaware of the underlying diagnosis.
MATERIALS AND METHODS
AIP diagnosis
The criteria for AIP diagnosis followed the European Porphyria
Network guidelines.1,38 AIP diagnosis and treatments were per-
formed in the French Porphyria Center, at the Louis Mourier
hospital. The ‘AIP patient’ status was defined by the association of at
least one AIP attack with a typical porphyrin and heme precursors
excretion profile in both urine and feces samples; the diagnosis was
confirmed by a 50% decrease in HMBS activity in erythrocytes, and
complemented by the identification of a causative mutation in
HMBS gene by direct sequencing, as previously described.39 Urinary
ALA and PBG were measured using the Bio-Rad ALA/PBG column
kit (Hercules, CA), according to the manufacturer’s protocol.
The ‘asymptomatic carrier’ status is defined after a family
screening to identify those with latent disease, and it is based on a
deficient HMBS enzymatic activity complemented with a DNA
analysis by direct sequencing to identify the causative mutation in the
HMBS gene (which requires prior identification of the mutation in a
related affected family member).
Study population
In 2003, a nationwide observational study surveyed a population of
415 patients (184 AIP patients and 231 asymptomatic carriers), who
provided a serum creatinine measurement. In 2013, these patients
were contacted by mail to provide detailed information including
AIP symptoms, presence of hypertension, or diabetes. Biological
analysis included serum creatinine, eGFR evaluation using the 4-
variable MDRD formula, ALA and PBG urinary concentrations, and
measurements of the protein-to-creatinine ratio in a morning urine
sample. The institutional review board of Louis Mourier Hospital
approved the study, written informed consent was obtained from all
patients, and the database has been deposited to the Commission
Nationale Informatique et Libertés (CNIL, agreement number
1187326).
Histology, electron microscopy, and immunochemistry
All the available renal biopsies taken from AIP patients included in
the 2013 cohort were retrospectively analyzed. Examinations of the
specimens were performed using standard Masson’s staining,
Marinozzi's silver stain, Perls coloration, and ultrastructural analysis
by electron microscopy. Immunohistochemistry for vimentin and
beta catenin was performed on the paraffin-embedded tissues as
described previously.17 For more details, see the ‘Extended Methods’
section in the Supplementary Appendix online.
Cell culture
HRECs were retrieved from human nephrectomy specimens and
isolated according to previously published methods, with minor
modifications40,41 (see the ‘Extended Methods’ section in the
Supplementary Appendix online). The concentration of ALA and
PBG used to incubate cells was 1 mmol/l to mimic the urinary
concentrations of ALA and PBG found during the AIP attacks.
Immunoblotting
Total protein lysates from HRECs were separated by SDS
polyacrylamide gel electrophoresis under denaturing conditions
and transferred to a PVDF membrane (GE Healthcare, Veĺizy-
Villacoublay, France). Primary antibodies were visualized using
horseradish peroxidase-conjugated polyclonal secondary antibodies
(Dako, Glostrup, Denmark) and detected using ECL reagent (GE
Healthcare). See the ‘Extended Methods’ section in the
Supplementary Appendix online.
Quantitative polymerase chain reaction
Transcript expression levels were measured by SYBR green qPCR
using an ABI PRISM 7900 sequence detector system (Applied
Biosystems, Fontenay-sous-Bois, France). Vehicle-treated samples
were used as controls, and fold changes for each tested gene were
normalized to the Ribosomal Protein L13A (RPL13A) housekeeping
gene. The relative expression levels were calculated using the
2(-ΔΔCT) method.42 For more details including the sequences of the
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primers, see the ‘Extended Methods’ section in the Supplementary
Appendix online.
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL)
TUNEL staining was performed with the In Situ Cell Death
Detection Kit, Fluorescein (Roche, Meylan, France), according to
the manufacturer’s instructions. Samples were counterstained with
DAPI to visualize nuclei. The number of TUNEL positive nuclei per
high power field was reported to the number of DAPI positive nuclei
to calculate the percentage of TUNEL positive nuclei on at least 4
fields (×100) per sample.
Fluorescence microscopy
Epifluorescence microscopy was performed on HRECs, which were
stained with Hoechst 33342 (2’-(4-ethoxyphenyl)-5-(4-methyl-1-
piperazinyl)-2.5’-bi-1H-benzimidazole) (Sigma Aldrich, St Louis,
MO) and propidium iodide (Invitrogen, Fontenay-sous-Bois,
France), as previously described.43 Indirect immunfluorescence to
detect slug and beta-catenin was perfomed using confocal microcopy
(see the ‘Extended Methods’ section in the Supplementary Appendix
online).
Enzyme-linked immunosorbent assay
The secretion of IL-6 and monocyte chemotactic protein-1 was
measured in the cell culture supernatant using the Quantikine
human IL6 and monocyte chemotactic protein-1 immunoassays
(R&D Systems, Minneapolis, MN) according to the manufacturer’s
protocol. neutrophil gelatinase-associated lipocalin concentrations in
urine samples was measured using the Quantikine human neutrophil
gelatinase-associated lipocalin immunoassay, according to the
manufacturer’s protocol.
Statistical analysis
The results for the categorical variables were expressed as
frequencies and percentages and for the continuous variables as
the mean± s.e.m. Associations between the clinical and biological
features of the patients were tested using Student’s t-test or the χ2 test
where appropriate. All tests were two sided, and a P-valueo0.05 was
considered statistically significant. Stratified odds ratio and χ2 were
obtained using the Cochran–Mantel–Haenzsel test. The statistical
analyses were performed using the R framework (available from:
http://www.R-project.org/).
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We thank Dany Anglicheau for providing MCP-1 ELISA.
SUPPLEMENTARY MATERIAL
Figure S1. Porphyrin metabolism and heme synthesis.
Figure S2. Urinary neutrophil gelatinase associated lipocalin
concentrations during AIP crisis.
Figure S3. Ultrastructure of tubules and arterioles.
Figure S4. Concentrations of PBG and uroporphyrinogen in HREC and
culture medium.
Figure S5. HREC incubated with ALA and PBG alone.
Figure S6. Effects of low concentrations of porphyrin precursors on
HREC.
Figure S7. Effect of porphyrin precursors on HUVEC.
Table S1. Characteristics of the 2003 cohort.
Table S2. Characteristics of the HMBS mutations in the 2013 cohort.
Table S3. Histopathology of PAKD.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet 2010; 375: 924–937.
2. Siegesmund M, van Tuyll van Serooskerken AM, Poblete-Gutierrez P et al.
The acute hepatic porphyrias: current status and future challenges.
Best Pract Res Clin Gastroenterol 2010; 24: 593–605.
3. Elder G, Harper P, Badminton M et al. The incidence of inherited
porphyrias in Europe. J Inherit Metab Dis 2013; 36: 849–857.
4. Nordmann Y, Puy H, Da Silva V et al. Acute intermittent porphyria:
prevalence of mutations in the porphobilinogen deaminase gene in
blood donors in France. J Intern Med 1997; 242: 213–217.
5. Herrick AL, McColl KE. Acute intermittent porphyria. Best Pract Res Clin
Gastroenterol 2005; 19: 235–249.
6. Anderson KE, Bloomer JR, Bonkovsky HL et al. Recommendations for the
diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005;
142: 439–450.
7. Andant C, Puy H, Bogard C et al. Hepatocellular carcinoma in patients
with acute hepatic porphyria: frequency of occurrence and related factors.
J Hepatol 2000; 32: 933–939.
8. Andant C, Puy H, Faivre J et al. Acute hepatic porphyrias and primary
liver cancer. N Engl J Med 1998; 338: 1853–1854.
9. Stewart MF. Review of hepatocellular cancer, hypertension and renal
impairment as late complications of acute porphyria and
recommendations for patient follow-up. J Clin Pathol 2012; 65: 976–980.
10. Andersson C, Wikberg A, Stegmayr B et al. Renal symptomatology in
patients with acute intermittent porphyria. A population-based study.
J Intern Med 2000; 248: 319–325.
11. Marsden JT, Chowdhury P, Wang J et al. Acute intermittent porphyria and
chronic renal failure. Clin Nephrol 2008; 69: 339–346.
12. Andersson C, Lithner F. Hypertension and renal disease in patients with
acute intermittent porphyria. J Intern Med 1994; 236: 169–175.
13. Sardh E, Andersson DE, Henrichson A et al. Porphyrin precursors and
porphyrins in three patients with acute intermittent porphyria and end-
stage renal disease under different therapy regimes. Cell Mol Biol 2009; 55:
66–71.
14. Castro AF, Coresh J. CKD surveillance using laboratory data from the
population-based National Health and Nutrition Examination Survey
(NHANES). Am J Kidney Dis 2009; 53: S46–S55.
15. Rule AD, Gussak HM, Pond GR et al. Measured and estimated GFR in
healthy potential kidney donors. Am J Kidney Dis 2004; 43: 112–119.
16. Hazzan M, Hertig A, Buob D et al. Epithelial-to-mesenchymal transition
predicts cyclosporine nephrotoxicity in renal transplant recipients. J Am
Soc Nephrol 2011; 22: 1375–1381.
17. Hertig A, Anglicheau D, Verine J et al. Early epithelial phenotypic changes
predict graft fibrosis. J Am Soc Nephrol 2008; 19: 1584–1591.
18. Marsden JT, Rees DC. Urinary excretion of porphyrins, porphobilinogen
and delta-aminolaevulinic acid following an attack of acute intermittent
porphyria. J Clin Pathol 2014; 67: 60–65.
19. Kepp O, Galluzzi L, Lipinski M et al. Cell death assays for drug discovery.
Nat Rev Drug Discov 2011; 10: 221–237.
20. Pallet N, Bouvier N, Bendjallabah A et al. Cyclosporine-induced
endoplasmic reticulum stress triggers tubular phenotypic changes
and death. Am J Transplant 2008; 8: 2283–2296.
21. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-
mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131–142.
22. Nochy D, Daugas E, Droz D et al. The intrarenal vascular lesions associated
with primary antiphospholipid syndrome. J Am Soc Nephrol 1999; 10:
507–518.
23. Chang CJ, Lee YH, Yang JY et al. Pilot in vitro toxicity study of 5-ALA and
Photofrin in microvascular endothelial cell cultures. J Clin Laser Med Surg
1997; 15: 83–87.
24. Middelburg TA, de Bruijn HS, Tettero L et al. Topical hexylaminolevulinate
and aminolevulinic acid photodynamic therapy: complete arteriole
vasoconstriction occurs frequently and depends on protoporphyrin IX
concentration in vessel wall. J Photochem Photobiol B 2013; 126: 26–32.
25. Lithner F. Could attacks of abdominal pain in cases of acute intermittent
porphyria be due to intestinal angina? J Intern Med 2000; 247: 407–409.
26. Kupferschmidt H, Bont A, Schnorf H et al. Transient cortical blindness and
bioccipital brain lesions in two patients with acute intermittent porphyria.
Ann Intern Med 1995; 123: 598–600.
394 Kidney International (2015) 88, 386–395
c l in i ca l inves t iga t ion N Pallet et al.: Acute intermittent porphyria and renal disease
27. Lai CW, Hung TP, Lin WS. Blindness of cerebral origin in acute intermittent
porphyria. Report of a case and postmortem examination. Arch Neurol
1977; 34: 310–312.
28. Celik M, Forta H, Dalkilic T et al. MRI reveals reversible lesions resembling
posterior reversible encephalopathy in porphyria. Neuroradiology 2002;
44: 839–841.
29. Soysal A, Dogan P, Dayan C et al. Reversible MRI findings of porphyric
encephalopathy. A report of two cases. Neuroradiol J 2008; 21: 655–659.
30. Lindberg RL, Porcher C, Grandchamp B et al. Porphobilinogen deaminase
deficiency in mice causes a neuropathy resembling that of human hepatic
porphyria. Nat Genet 1996; 12: 195–199.
31. Unzu C, Sampedro A, Sardh E et al. Renal failure affects the enzymatic
activities of the three first steps in hepatic heme biosynthesis in the acute
intermittent porphyria mouse. PLoS One 2012; 7: e32978.
32. Viau A, El Karoui K, Laouari D et al. Lipocalin 2 is essential for chronic
kidney disease progression in mice and humans. J Clin Invest 2010; 120:
4065–4076.
33. De Siervi A, Vazquez ES, Rezaval C et al. Delta-aminolevulinic acid cytotoxic
effects on human hepatocarcinoma cell lines. BMC Cancer 2002; 2: 6.
34. Zhang XL, Topley N, Ito T et al. Interleukin-6 regulation of transforming
growth factor (TGF)-beta receptor compartmentalization and turnover
enhances TGF-beta1 signaling. J Biol Chem 2005; 280: 12239–12245.
35. Dai Y, Zhang W, Wen J et al. A2B adenosine receptor-mediated induction
of IL-6 promotes CKD. J Am Soc Nephrol 2011; 22: 890–901.
36. Zhang W, Wang W, Yu H et al. Interleukin 6 underlies angiotensin II-
induced hypertension and chronic renal damage. Hypertension 2012;
59: 136–144.
37. He G, Dhar D, Nakagawa H et al. Identification of liver cancer progenitors
whose malignant progression depends on autocrine IL-6 signaling.
Cell 2013; 155: 384–396.
38. Tollanes MC, Aarsand AK, Villanger JH et al. Establishing a network of
specialist Porphyria centres - effects on diagnostic activities and services.
Orphanet J Rare Dis 2012; 7: 93.
39. Puy H, Deybach JC, Lamoril J et al. Molecular epidemiology and diagnosis
of PBG deaminase gene defects in acute intermittent porphyria. Am J
Hum Genet 1997; 60: 1373–1383.
40. Tang S, Leung JC, Abe K et al. Albumin stimulates interleukin-8 expression
in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 2003;
111: 515–527.
41. Pallet N, Thervet E, Le Corre D et al. Rapamycin inhibits human renal
epithelial cell proliferation: effect on cyclin D3 mRNA expression and
stability. Kidney Int 2005; 67: 2422–2433.
42. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001; 25: 402–408.
43. Sirois I, Groleau J, Pallet N et al. Caspase activation regulates the
extracellular export of autophagic vacuoles. Autophagy 2012; 8:
927–937.
Kidney International (2015) 88, 386–395 395
N Pallet et al.: Acute intermittent porphyria and renal disease c l i n i ca l inves t iga t ion
